Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites

Completed · Phase 2

Conditions studied: Ascites, Liver Cirrhosis

In brief

The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites and the correction of hyponatraemia when used concomitantly with a standard dose regimen of spironolactone. The secondary objective is to determine the tolerability of different fixed doses of SR121463B over a 14 day treatment period in cirrhotic ascites. This Hypo\~CAT study is followed by a single-blind, placebo-controlled, one-year long-term safety extension (Expo\~CAT). The first extension is followed by another long-term study (PASCCAL-1).

Key facts

Study ID
NCT00501722
Run by
Sanofi
People needed
110
Starts
2004-04-01
Expected to finish
2005-03-01
Last updated by the study team
2009-01-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.